Perineline™
Spinal Cord Injury
Phase 1Active
Key Facts
About NeuroSolv Therapeutics
NeuroSolv Therapeutics is a clinical-stage biotech developing Perineline™, a novel small molecule therapy for spinal cord injury. The company achieved a key regulatory milestone in March 2022 with EMA Orphan Drug Designation for Perineline™, which provides a pathway for accelerated development and market authorization in major regions. NeuroSolv is now preparing to initiate a clinical trial in partnership with a leading US spinal cord trauma hospital, positioning the company to advance a potentially transformative treatment for a condition with significant unmet need.
View full company profileTherapeutic Areas
Other Spinal Cord Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC‑SCI | Advancells | Phase 1 |
| itNSCs | Stemedica Cell Technologies | Development |
| MAP4343 | Mapreg | Preclinical |
| Spinal Cord Injury Program | BioAxone Biosciences | Clinical |
| Undisclosed Scaffold Program | Innervace | Pre-clinical |
| Q-Cells | Q Therapeutics | Research |
| APOSEC | Aposcience | Pre-clinical |
| NG004 | Neurimmune | Phase 1 |
| Nogo-A Receptor Blocking Antibody | NovaGo Therapeutics | Phase 1b |
| Spinal Cord Injury (SCI) Neural Bridge | Matricelf | Preclinical |